Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Researchers found that treating precancerous pancreatic lesions with experimental KRAS inhibitors slowed tumor development ...

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics ...

Pioneering clinical trial testing how personalised mRNA vaccines can enable the immune system to target recurring pancreatic cancer.

The firm previously held rights to develop and commercialize ERAS-0015 in territories outside of China, Hong Kong, and Macau.

A new study isolated DNA from the tumours of 500 cats across 13 different tumour types and mapped the sequence of 1,000 genes often found mutated in human cancers.

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class ...

In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test ...